Outset Medical, Inc. (NASDAQ:OM) Stock Has Consensus Price Target of $10.00 According to Analysts

Outset Medical, Inc. (NASDAQ:OM) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $10.00.

OM has been the topic of several analyst reports. Weiss Ratings downgraded shares of Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th.

Outset Medical Stock Down 2.9%

Shares of NASDAQ:OM opened at $4.09 on Friday. The company has a current ratio of 5.19, a quick ratio of 4.11 and a debt-to-equity ratio of 1.03. The firm has a market cap of $76.89 million, a PE ratio of -1.00 and a beta of 1.99. Outset Medical has a 12-month low of $2.84 and a 12-month high of $16.16. The company has a fifty day simple moving average of $3.90 and a 200 day simple moving average of $4.19.

Outset Medical (NASDAQ:OM) last released its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%.The firm had revenue of $31.64 million during the quarter, compared to analyst estimates of $28.97 million. On average, equities research analysts anticipate that Outset Medical will post -3.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Outset Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BML Capital Management LLC increased its holdings in shares of Outset Medical by 250.2% in the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after purchasing an additional 1,359,021 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Outset Medical by 391.3% during the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock worth $853,000 after buying an additional 176,870 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Outset Medical by 4.1% during the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock worth $239,000 after buying an additional 2,435 shares in the last quarter. Marquette Asset Management LLC bought a new position in Outset Medical in the 2nd quarter valued at $212,000. Finally, Aristides Capital LLC bought a new position in Outset Medical in the 4th quarter valued at $177,000.

Outset Medical Company Profile

Outset Medical, Inc is a medical technology company focused on improving the delivery of hemodialysis. The company develops products intended to simplify dialysis treatment, expand access to care and support the movement of treatment into more convenient clinical and home settings.

Its primary product is the Tablo Hemodialysis System, an integrated dialysis platform designed to automate and streamline the preparation and delivery of treatment. The system combines dialysis hardware, water purification and software-based user guidance in a single platform.